View Older Stories View More Recent Stories

Sep 17, 2020 01:44PM Eli Lilly (LLY) Said Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19
Sep 17, 2020 01:41PM Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
Sep 17, 2020 06:31AM Lilly (LLY) and Amgen (AMGN) Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Sep 17, 2020 06:30AM Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Sep 16, 2020 04:56PM Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
Sep 15, 2020 08:05AM Lilly (LLY) announces US FDA grants Fast Track designation to Jardiance to improve outcomes following a heart attack
Sep 15, 2020 08:00AM US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack
Sep 10, 2020 12:00PM Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes
Sep 3, 2020 05:14PM Eli Lilly & Co. (LLY) announces FDA approves additional doses of Trulicity for treatment of type 2 diabetes
Sep 3, 2020 05:12PM FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes
Aug 29, 2020 06:00AM Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection frac
Jul 30, 2020 06:15AM Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Jun 24, 2020 08:30AM Lilly launches program about what people with diabetes should "Know Before the Low™"
Jun 19, 2020 08:37PM Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
Jun 19, 2020 12:25PM Full results from EMPERIAL exercise ability trials presented
Jun 18, 2020 08:05AM Eli Lilly & Co. (LLY) Initiates Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
Jun 18, 2020 08:00AM Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
Jun 15, 2020 10:21PM FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin
Jun 13, 2020 11:15AM Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
Jun 12, 2020 03:47PM Lilly (LLY) and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life
Jun 12, 2020 03:46PM Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life
Jun 10, 2020 03:19PM EULAR 2020: Lilly Shares New Data for OLUMIANT® in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)
Jun 9, 2020 06:45AM First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial
Jun 5, 2020 06:09PM EULAR 2020: Lilly’s TALTZ® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
May 26, 2020 05:51PM Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model
May 26, 2020 08:00AM Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction
May 8, 2020 02:28PM Lilly (LLY) reports higher investigational doses of Trulicity meaningfully reduced A1C and body weight in people with type 2 diabetes
May 8, 2020 02:20PM Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes
Apr 16, 2020 06:45AM Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available
Apr 7, 2020 06:30AM New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Mar 24, 2020 08:11AM Eli Lilly (LLY) does not currently anticipate shortages for any of our medicines, including all forms of insulin
Mar 24, 2020 08:00AM Updates from Lilly about insulin supply and affordability
Mar 20, 2020 04:32PM Lilly (LLY) announces US FDA issues CRL for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Mar 20, 2020 04:30PM US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Mar 12, 2020 08:04AM Boehringer Ingelheim and Lilly (LLY) announces FDA grants Fast Track designation to Jardiance for treatment of chronic kidney disease
Mar 12, 2020 08:00AM US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease
Mar 11, 2020 12:36PM Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D
Mar 2, 2020 06:47AM Pfizer (PFE) and Lilly (LLY) announce FDA accepted for review BLA for tanezumab 2.5 mg administered subcutaneously
Mar 2, 2020 06:45AM U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
Feb 21, 2020 07:50PM Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease
Feb 12, 2020 05:54AM Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib
Feb 11, 2020 06:24PM Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti
Feb 11, 2020 06:52AM Eli Lilly Canada (LLY) Announces Health Canada has approved TALTZ for Treatment of Active Ankylosing Spondylitis
Feb 11, 2020 06:45AM Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Jan 28, 2020 06:45AM Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Jan 27, 2020 05:36PM Eli Lilly & Co. (LLY) announces FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes
Jan 27, 2020 05:34PM US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
Jan 23, 2020 08:00AM Ready for Rescue – New Nasally Administered Glucagon for Severe Hypoglycemia Available in Canada
View More Recent Stories View Older Stories